A MULTICENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, TWOPART, RANDOMIZED, PHASE 2 CLINICAL TRIAL TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OFBB-031 IN ACUTE ISCHEMIC STROKE (AIS) PATIENTS

Registry ID

BB-031-CLIN-201

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

BASKING BIOSCIENCES, INC

Start date

2025-11-11

Last update

2024-10-01

Conditions

• ACUTE ISCHEMIC STROKE

Related clinical trials

• OPTIMIZING REPERFUSION TO IMPROVE OUTCOMES AND NEUROLOGIC FUNCTION (ORION): A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, PARALLEL-GROUP, PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JX10 IN ACUTE ISCHEMIC STROKE WITH LATE PRESENTATIONS
• PHASE 2/3 ADAPTIVE DESIGN, RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DM199 FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE (REMEDY2 TRIAL)
• THE ACT RRCT- ALTEPLASE COMPARED TO TENECTEPLASE IN PATIENTS WITH ACUTE ISCHEMIC STROKE:QUICR & OPTIMISE REGISTRY BASED PRAGMATIC RANDOMIZED CONTROLLED TRIAL

View on source registry